S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR. (23rd June 2022) - Verstovsek, S.; Vannucchi, A.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; et al.